InspireMD, Inc. (NYSE:NSPR) Short Interest Update

Key Points

• InspireMD, Inc. experienced a significant decrease in short interest, with a drop of 58.1% to 127,300 shares as of August 31, indicating a lower bearish sentiment among investors.
• Insider trading activity included Director Gary S. Roubin purchasing 41,322 shares and Director Paul Stuka acquiring 20,661 shares, reflecting confidence in the company's future.
• Currently, 44.78% of InspireMD's stock is held by institutional investors, indicating notable interest from larger market players.

InspireMD, Inc. (NYSE:NSPR - Get Free Report) saw a significant decline in short interest during the month of August. As of August 31st, there was short interest totaling 127,300 shares, a decline of 58.1% from the August 15th total of 304,000 shares. Based on an average trading volume of 180,500 shares, the days-to-cover ratio is currently 0.7 days. Approximately 0.7% of the company's shares are sold short. Approximately 0.7% of the company's shares are sold short. Based on an average trading volume of 180,500 shares, the days-to-cover ratio is currently 0.7 days.

InspireMD Price Performance

Shares of NSPR traded up $0.02 during mid-day trading on Thursday, reaching $2.42. 63,251 shares of the company's stock traded hands, compared to its average volume of 98,521. The stock has a market cap of $100.96 million, a P/E ratio of -3.23 and a beta of 0.68. The stock's 50-day moving average is $2.45 and its two-hundred day moving average is $2.51. InspireMD has a 12 month low of $1.99 and a 12 month high of $3.80.

Insiders Place Their Bets

In related news, Director Gary S. Roubin acquired 41,322 shares of InspireMD stock in a transaction on Wednesday, July 30th. The shares were bought at an average cost of $2.42 per share, with a total value of $99,999.24. Following the completion of the purchase, the director directly owned 608,425 shares of the company's stock, valued at $1,472,388.50. The trade was a 7.29% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Thomas J. Kester bought 30,991 shares of the business's stock in a transaction dated Wednesday, July 30th. The shares were acquired at an average cost of $2.42 per share, for a total transaction of $74,998.22. Following the purchase, the director owned 420,758 shares of the company's stock, valued at approximately $1,018,234.36. The trade was a 7.95% increase in their position. The disclosure for this purchase can be found here. Insiders have purchased 103,304 shares of company stock valued at $249,996 over the last ninety days. 34.06% of the stock is owned by insiders.

Institutional Trading of InspireMD

Large investors have recently modified their holdings of the company. Northern Trust Corp boosted its holdings in shares of InspireMD by 103.7% in the fourth quarter. Northern Trust Corp now owns 48,022 shares of the company's stock valued at $126,000 after purchasing an additional 24,452 shares during the period. Parkman Healthcare Partners LLC boosted its holdings in shares of InspireMD by 37.1% in the first quarter. Parkman Healthcare Partners LLC now owns 1,171,416 shares of the company's stock valued at $3,151,000 after purchasing an additional 316,700 shares during the period. Brown Advisory Inc. purchased a new stake in shares of InspireMD in the first quarter valued at approximately $27,000. Nantahala Capital Management LLC boosted its holdings in shares of InspireMD by 38.4% in the first quarter. Nantahala Capital Management LLC now owns 2,318,017 shares of the company's stock valued at $6,235,000 after purchasing an additional 643,452 shares during the period. Finally, Huntleigh Advisors Inc. purchased a new stake in shares of InspireMD in the first quarter valued at approximately $316,000. Hedge funds and other institutional investors own 44.78% of the company's stock.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.